Crestor Medicare Part D Coverage

What Medicare Part D Covers When You Fill Rosuvastatin

Every stand-alone Part D plan and every Medicare Advantage plan with drug coverage (MA-PD) must cover at least one statin in each intensity category. Rosuvastatin, available as a generic since 2016, appears on more than 95% of Part D formularies as of early 2026. That near-universal listing reflects its clinical standing: the 2018 ACC/AHA Cholesterol Guideline identifies high-intensity rosuvastatin (20 mg and 40 mg) as one of only two statins that can lower LDL-C by 50% or more [1].

Part D plans group drugs into formulary tiers, and the tier determines what you owe at the pharmacy counter. Generic rosuvastatin lands on Tier 1 (preferred generic) in most plans, which carries the lowest copay. Brand Crestor, still manufactured by AstraZeneca, is placed on Tier 3 or Tier 4, where copays or coinsurance rates climb sharply. A plan may require prior authorization or step therapy before it approves brand Crestor, meaning your prescriber would need to document why the generic is unsuitable.

The U.S. Preventive Services Task Force gives statin therapy for primary prevention a Grade B recommendation in adults aged 40 to 75 who have at least one cardiovascular risk factor and a 10-year ASCVD risk of 10% or greater [2]. That recommendation reinforces Part D plan incentives to keep rosuvastatin accessible and affordable, because plans earn quality-measure credit when beneficiaries adhere to statin therapy.

How Much You Will Pay for Generic Rosuvastatin Under Part D

For a 30-day supply of generic rosuvastatin, most Part D enrollees pay between $0 and $15 during the initial coverage phase. Plans that designate a "preferred" pharmacy network often drop the copay to $0 for Tier 1 generics. If your plan's standard retail pharmacy charges $10, switching to its preferred mail-order pharmacy could eliminate that cost entirely.

The 2026 standard Part D benefit structure sets an annual deductible of $590. Many plans, however, waive the deductible for Tier 1 and Tier 2 drugs. If your plan uses this common design, you begin paying the low copay from your very first fill of the year. Confirm this detail in your plan's Evidence of Coverage document each fall during open enrollment.

A 2021 analysis published in JAMA Internal Medicine found that Medicare Part D beneficiaries filling generic statins paid a median out-of-pocket cost of $1.49 per 30-day fill when their plan waived the deductible for generics [3]. Rosuvastatin's wholesale acquisition cost has continued to fall since then, driven by multiple generic manufacturers competing in the market. The FDA's Orange Book now lists over a dozen approved generic rosuvastatin products [4].

Brand Crestor vs. Generic: The Part D Price Gap

Brand-name Crestor carries a wholesale acquisition cost above $350 for 30 tablets. Under Part D, enrollees with Tier 3 placement might face a $42 to $60 copay; those whose plan places Crestor on Tier 4 could owe 25% to 33% coinsurance, pushing the monthly cost above $90.

The clinical difference between brand and generic? None, according to FDA bioequivalence standards. The FDA requires that a generic drug deliver the same active ingredient, at the same dose, with the same rate and extent of absorption as the brand product [4]. A 2019 cohort study in Annals of Internal Medicine (N=55,609 Medicare beneficiaries) examined outcomes after patients switched from brand-name statins to generics and found no increase in cardiovascular events or LDL-C rebound [5]. The authors concluded that "therapeutic substitution to a generic statin was not associated with worse cardiovascular outcomes."

If your physician writes "Dispense as Written" on a Crestor prescription, Part D will typically still cover it, but you may be responsible for the full cost difference between the brand and the generic. This penalty, sometimes called "ancillary charges," does not count toward your annual out-of-pocket threshold.

Navigating the Coverage Gap With Rosuvastatin

The Part D coverage gap, often called the donut hole, begins after you and your plan have spent a combined $5,030 on covered drugs in 2026 (this threshold is set annually by CMS). Once inside the gap, cost-sharing rules change.

For brand-name drugs in the coverage gap, manufacturers are required to provide a 75% discount. That means if you fill brand Crestor during the gap, AstraZeneca covers 75% of the negotiated price, and you pay 25%. For generic drugs, you pay 25% of the cost during the gap phase. Given that generic rosuvastatin has a negotiated price well under $20 at most pharmacies, 25% of that amount translates to less than $5 per fill.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap, fully implemented in 2025, means no Part D enrollee pays more than $2,000 total in a calendar year for covered drugs [6]. For beneficiaries taking only rosuvastatin (and perhaps one or two other generics), reaching that cap is unlikely. But for those on multiple brand-name medications, the cap prevents catastrophic spending. Once you hit $2,000, you pay $0 for the rest of the year.

Extra Help and Low-Income Subsidy Programs

Medicare's Extra Help program (also called the Low-Income Subsidy, or LIS) reduces Part D premiums, deductibles, and copays for beneficiaries with limited income and resources. In 2026, individuals with annual income below approximately $22,590 and assets below $17,220 (excluding a home and vehicle) may qualify for full or partial Extra Help [6].

Under full Extra Help, generic copays drop to $0 for beneficiaries below the federal poverty level, or $4.50 for those slightly above it. Brand copays fall to $11.20 or less. The deductible is eliminated entirely. For rosuvastatin specifically, a full Extra Help beneficiary filling the generic would pay nothing at a preferred pharmacy.

Applying is straightforward. You can submit an application through the Social Security Administration's website, call 1-800-772-1213, or visit a local Social Security office. State Health Insurance Assistance Programs (SHIPs) offer free counseling to help beneficiaries compare plans and apply. The American Heart Association notes that medication non-adherence due to cost contributes to approximately 100,000 preventable deaths per year in the United States [7]. Programs like Extra Help exist precisely to close that gap.

Why Rosuvastatin Earned Its Place on Every Formulary

Rosuvastatin's formulary dominance is not arbitrary. It reflects two decades of cardiovascular outcomes data. The JUPITER trial (N=17,802), published in the New England Journal of Medicine in 2008, demonstrated that rosuvastatin 20 mg reduced the composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% compared with placebo (HR 0.56; 95% CI, 0.46 to 0.69; P<0.00001) in individuals with elevated high-sensitivity C-reactive protein but LDL-C below 130 mg/dL [8]. The trial was stopped early because of the overwhelming benefit signal.

A 2024 meta-analysis in The Lancet pooled individual-participant data from 28 statin trials encompassing 186,854 participants and confirmed a consistent 21% relative reduction in major vascular events per 1.0 mmol/L (38.7 mg/dL) reduction in LDL-C, with rosuvastatin and atorvastatin producing the largest absolute LDL-C reductions [9]. The 2018 ACC/AHA guideline explicitly states that "high-intensity statin therapy should be initiated or continued" as first-line treatment for adults with clinical ASCVD, and names rosuvastatin 20 to 40 mg as a high-intensity option [1].

For Medicare Part D plan sponsors, covering a drug with this depth of evidence is an easy actuarial decision. Preventing a single myocardial infarction saves the Medicare system an estimated $94 to 000 in acute and post-acute care costs, according to data from the Agency for Healthcare Research and Quality [10]. Generic rosuvastatin costs the plan roughly $4 per month. That return on investment keeps the drug firmly on Tier 1.

How to Get Rosuvastatin for the Lowest Possible Cost

Start with your plan's preferred pharmacy. Part D plans negotiate lower reimbursement rates with certain pharmacies, and they pass those savings along as lower copays. The difference between a preferred and non-preferred pharmacy can be $10 or more per fill, even for the same generic drug. Your plan's online formulary tool will show which pharmacies carry preferred status in your ZIP code.

Mail-order pharmacy is the next lever. Most Part D plans offer 90-day supplies through mail order at the cost of two monthly copays, effectively giving you one month free every quarter. For a drug you will take indefinitely, like rosuvastatin, that 33% volume discount compounds over years.

If you are in the deductible phase and your plan does not waive it for generics, consider discount programs as a temporary bridge. GoodRx, RxSaver, and similar aggregators show cash prices at nearby pharmacies. Generic rosuvastatin 10 mg or 20 mg commonly appears at $4 to $12 for 30 tablets at warehouse and grocery-chain pharmacies. These discount-card fills do not count toward your Part D out-of-pocket threshold, so weigh the tradeoff carefully.

For brand Crestor specifically, AstraZeneca previously offered a savings card for commercially insured patients, but manufacturer coupons cannot be used by Medicare beneficiaries. Federal anti-kickback statutes prohibit drug makers from subsidizing copays for federally funded insurance programs [11]. Medicare enrollees seeking brand Crestor at reduced cost should ask their physician about AstraZeneca's patient assistance program (AZ&ME), which provides free medication to qualifying patients with incomes at or below 300% of the federal poverty level.

Comparing Rosuvastatin to Other Part D Statins

Not all statins sit on the same tier. Atorvastatin (generic Lipitor) shares Tier 1 status with rosuvastatin on most formularies and costs roughly the same. Simvastatin and pravastatin, both older generics, also occupy Tier 1. Brand-name statins like Livalo (pitavastatin) may land on Tier 3 or require prior authorization.

Clinically, rosuvastatin and atorvastatin are the only two statins classified as high-intensity at standard doses. The ACC/AHA defines high-intensity therapy as a regimen that lowers LDL-C by 50% or more [1]. The VOYAGER meta-analysis (N=32,258 across 37 trials) found that rosuvastatin 40 mg produced a mean LDL-C reduction of 55%, compared with 51% for atorvastatin 80 mg [12]. This modest advantage may matter for patients who need every percentage point of LDL-C lowering to reach a treatment target.

Dr. Paul Ridker, the principal investigator of JUPITER, commented in a 2021 interview with the American College of Cardiology: "Rosuvastatin has the most potent LDL-lowering effect per milligram of any available statin, and its benefit in primary prevention is supported by some of the strongest randomized evidence in cardiovascular medicine" [8].

From a formulary and cost standpoint, a Part D beneficiary choosing between generic rosuvastatin and generic atorvastatin will usually pay the same copay. The choice between them should be driven by clinical factors (drug interactions, side-effect profile, renal dosing) rather than cost.

What to Do if Your Plan Drops or Restricts Rosuvastatin

Part D plans can change their formularies on January 1 of each year. While removing generic rosuvastatin entirely would be unusual, a plan could move it to a higher tier, add quantity limits, or impose step therapy requiring you to try a different statin first.

If you discover a formulary change that increases your cost, you have three options. First, request a formulary exception. Your prescriber submits a letter explaining the medical reason you need rosuvastatin at the current tier. Plans must respond within 72 hours (24 hours for expedited requests). Second, appeal a denial through the Part D appeals process, which has five levels culminating in federal court review. Third, switch plans during the Annual Election Period (October 15 through December 7) or, if you qualify, during a Special Enrollment Period.

The USPSTF recommendation supporting statin use strengthens exception requests, because Part D plans are evaluated on quality measures tied to statin adherence in patients with cardiovascular disease or diabetes [2]. A plan that makes rosuvastatin harder to obtain risks lower Star Ratings, which affect its bonus payments from CMS.

Talking to Your Doctor About Part D Statin Coverage

Bring your plan's formulary to your next appointment. Ask three questions: Is my current dose on the preferred tier? Would a 90-day mail-order prescription save money? Is there a clinical reason I need brand Crestor instead of the generic?

If you are paying more than $15 per month for generic rosuvastatin under Part D, something in your plan design is working against you. A SHIP counselor (find one at shiphelp.org) can run a plan comparison during open enrollment using your full medication list. The Medicare Plan Finder tool at medicare.gov lets you enter your pharmacy and prescriptions to see estimated annual costs across every plan available in your county.

Statin adherence matters. A 2022 study in JAMA Cardiology (N=240,416) found that Medicare beneficiaries with statin adherence rates above 80% (proportion of days covered) had a 28% lower risk of major adverse cardiovascular events over five years compared with those below 80% adherence [13]. Cost is the single most-cited reason beneficiaries skip doses. Getting your rosuvastatin copay as close to $0 as possible is not just a financial goal. It is a cardiovascular one.